Clinical relevance of growth factor antagonists in the treatment of benign prostatic hyperplasia.
Changing demography and expectations about maintaining quality of life mean that an increasing number of men will require treatment for benign prostatic hyperplasia (BPH). Many growth factors have a role in the development of BPH. Consequently growth factor antagonists offer an attractive therapeutic option. In double-blind randomised trials Tadenan, a drug known to have growth factor antagonist activity, conferred significant improvement of urinary symptoms, maximum flow rate and residual volume, with no serious side-effects. Therapeutic outcome could be enhanced in a number of ways including matching patients with particular cell type overgrowth for treatment with a growth factor antagonist specific for that cell type. Full exploitation of this approach awaits the development of less invasive means of determining the cell type affected.
Desgrandchamps
F
F
Department of Urology, Hôpital Saint-Louis, Paris, France.
D005233:Fatty Alcohols / Q000627:therapeutic use; D006131:Growth Inhibitors / Q000627:therapeutic use*; D006133:Growth Substances / Q000502:physiology; D006801:Humans; D008297:Male; D010936:Plant Extracts / Q000627:therapeutic use; D011470:Prostatic Hyperplasia / Q000188:drug therapy* / Q000209:etiology
D005233:Fatty Alcohols; D006131:Growth Inhibitors; D006133:Growth Substances; D010936:Plant Extracts; C009375:Tadenan